Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enrollment Headaches Cause NMT To Drop Migraine Trial

This article was originally published in The Gray Sheet

Executive Summary

NMT Medical is halting its chase of a migraine indication for its patent foramen ovale closure device after an earlier trial missed its primary endpoint and a second, larger trial has suffered enrollment problems

You may also be interested in...



SeptRx Launches PFO Device Trial, Eyeing Mid-2012 CE-Mark Submission

Controversy remains over the clinical benefit of using a patent foramen ovale closure device to prevent strokes or other neurological events, but that has not stopped California startup SeptRx from moving ahead with early stage development of its offering.

SeptRx Launches PFO Device Trial, Eyeing Mid-2012 CE-Mark Submission

Controversy remains over the clinical benefit of using a patent foramen ovale closure device to prevent strokes or other neurological events, but that has not stopped California startup SeptRx from moving ahead with early stage development of its offering.

Will Positive PFO Closure Trials For Stroke Help Or Hurt Other Indications?

As pivotal trials for patent foramen ovale (PFO) closure devices to treat stroke start wrapping up, cardiologists are questioning what impact the trial results will have on studies for other indications

Related Content

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel